Effects of the new calcium antagonist 2-nitratopropyl 3-nitratopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate on cerebral circulation in cats

J. Kawamura, F. Gotoh, Y. Fukuuchi, T. Amano, K. Tanaka, D. Uematsu, N. Suzuki, M. Kobari, K. Obara

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Effects of CD-349 (2-nitratopropyl 3-nitratopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate) on cerebral circulation were studied in 10 cats. The cats were fixed in a stereotactic head-holder, and two burr holes were made at 3-mm intervals over the left parietal cortex. Through one cranial window, the pial artery and vein diameters were measured continuously by a newly developed videocamera system in conjuction with a width analyzer, and the other one was used for measurement of cerebral blood volume (CBV). The pial artery (141 ± 14 μm) was dilated by 16.6 ± 4.9% (p < 0.01) 1 min and 24.8 ± 5.1% (p < 0.01) 5 min after the CD-349 injection. The pial vein (101 ± 20 μm) was also dilated with the percent increase of the diameter being 11.4 ± 4.0% (p < 0.01) 1 min and 11.3 ± 4.9% (p < 0.05) 5 min after the CD-349 administration. The CBV was also increased. The mean arterial blood pressure was decreased by 39.8 ± 7.3 mmHg (p < 0.01) 1 min and 34.4 ± 5.5 mmHg (p < 0.01) 5 min after drug injection. Thereafter, the blood pressure gradually returned to the pre-drug level. From these results it is suggested that CD-349 exerts direct vasodilatory action via inhibition of calcium influx across vascular cell membranes into cerebral vessels.

Original languageEnglish
Pages (from-to)221-224
Number of pages4
JournalArzneimittel-Forschung/Drug Research
Volume38
Issue number2
Publication statusPublished - 1988

Fingerprint

Cerebrovascular Circulation
Cats
Calcium
Cerebral Veins
Blood pressure
Arterial Pressure
Blood
Arteries
Parietal Lobe
Injections
Cell membranes
Pharmaceutical Preparations
Blood Vessels
Head
Cell Membrane
CD 349
Blood Pressure

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Effects of the new calcium antagonist 2-nitratopropyl 3-nitratopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate on cerebral circulation in cats. / Kawamura, J.; Gotoh, F.; Fukuuchi, Y.; Amano, T.; Tanaka, K.; Uematsu, D.; Suzuki, N.; Kobari, M.; Obara, K.

In: Arzneimittel-Forschung/Drug Research, Vol. 38, No. 2, 1988, p. 221-224.

Research output: Contribution to journalArticle

Kawamura, J, Gotoh, F, Fukuuchi, Y, Amano, T, Tanaka, K, Uematsu, D, Suzuki, N, Kobari, M & Obara, K 1988, 'Effects of the new calcium antagonist 2-nitratopropyl 3-nitratopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate on cerebral circulation in cats', Arzneimittel-Forschung/Drug Research, vol. 38, no. 2, pp. 221-224.
Kawamura, J. ; Gotoh, F. ; Fukuuchi, Y. ; Amano, T. ; Tanaka, K. ; Uematsu, D. ; Suzuki, N. ; Kobari, M. ; Obara, K. / Effects of the new calcium antagonist 2-nitratopropyl 3-nitratopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate on cerebral circulation in cats. In: Arzneimittel-Forschung/Drug Research. 1988 ; Vol. 38, No. 2. pp. 221-224.
@article{0371d7853d70495b9bdfe9ab5891e9cd,
title = "Effects of the new calcium antagonist 2-nitratopropyl 3-nitratopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate on cerebral circulation in cats",
abstract = "Effects of CD-349 (2-nitratopropyl 3-nitratopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate) on cerebral circulation were studied in 10 cats. The cats were fixed in a stereotactic head-holder, and two burr holes were made at 3-mm intervals over the left parietal cortex. Through one cranial window, the pial artery and vein diameters were measured continuously by a newly developed videocamera system in conjuction with a width analyzer, and the other one was used for measurement of cerebral blood volume (CBV). The pial artery (141 ± 14 μm) was dilated by 16.6 ± 4.9{\%} (p < 0.01) 1 min and 24.8 ± 5.1{\%} (p < 0.01) 5 min after the CD-349 injection. The pial vein (101 ± 20 μm) was also dilated with the percent increase of the diameter being 11.4 ± 4.0{\%} (p < 0.01) 1 min and 11.3 ± 4.9{\%} (p < 0.05) 5 min after the CD-349 administration. The CBV was also increased. The mean arterial blood pressure was decreased by 39.8 ± 7.3 mmHg (p < 0.01) 1 min and 34.4 ± 5.5 mmHg (p < 0.01) 5 min after drug injection. Thereafter, the blood pressure gradually returned to the pre-drug level. From these results it is suggested that CD-349 exerts direct vasodilatory action via inhibition of calcium influx across vascular cell membranes into cerebral vessels.",
author = "J. Kawamura and F. Gotoh and Y. Fukuuchi and T. Amano and K. Tanaka and D. Uematsu and N. Suzuki and M. Kobari and K. Obara",
year = "1988",
language = "English",
volume = "38",
pages = "221--224",
journal = "Drug Research",
issn = "2194-9379",
publisher = "Thieme",
number = "2",

}

TY - JOUR

T1 - Effects of the new calcium antagonist 2-nitratopropyl 3-nitratopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate on cerebral circulation in cats

AU - Kawamura, J.

AU - Gotoh, F.

AU - Fukuuchi, Y.

AU - Amano, T.

AU - Tanaka, K.

AU - Uematsu, D.

AU - Suzuki, N.

AU - Kobari, M.

AU - Obara, K.

PY - 1988

Y1 - 1988

N2 - Effects of CD-349 (2-nitratopropyl 3-nitratopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate) on cerebral circulation were studied in 10 cats. The cats were fixed in a stereotactic head-holder, and two burr holes were made at 3-mm intervals over the left parietal cortex. Through one cranial window, the pial artery and vein diameters were measured continuously by a newly developed videocamera system in conjuction with a width analyzer, and the other one was used for measurement of cerebral blood volume (CBV). The pial artery (141 ± 14 μm) was dilated by 16.6 ± 4.9% (p < 0.01) 1 min and 24.8 ± 5.1% (p < 0.01) 5 min after the CD-349 injection. The pial vein (101 ± 20 μm) was also dilated with the percent increase of the diameter being 11.4 ± 4.0% (p < 0.01) 1 min and 11.3 ± 4.9% (p < 0.05) 5 min after the CD-349 administration. The CBV was also increased. The mean arterial blood pressure was decreased by 39.8 ± 7.3 mmHg (p < 0.01) 1 min and 34.4 ± 5.5 mmHg (p < 0.01) 5 min after drug injection. Thereafter, the blood pressure gradually returned to the pre-drug level. From these results it is suggested that CD-349 exerts direct vasodilatory action via inhibition of calcium influx across vascular cell membranes into cerebral vessels.

AB - Effects of CD-349 (2-nitratopropyl 3-nitratopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate) on cerebral circulation were studied in 10 cats. The cats were fixed in a stereotactic head-holder, and two burr holes were made at 3-mm intervals over the left parietal cortex. Through one cranial window, the pial artery and vein diameters were measured continuously by a newly developed videocamera system in conjuction with a width analyzer, and the other one was used for measurement of cerebral blood volume (CBV). The pial artery (141 ± 14 μm) was dilated by 16.6 ± 4.9% (p < 0.01) 1 min and 24.8 ± 5.1% (p < 0.01) 5 min after the CD-349 injection. The pial vein (101 ± 20 μm) was also dilated with the percent increase of the diameter being 11.4 ± 4.0% (p < 0.01) 1 min and 11.3 ± 4.9% (p < 0.05) 5 min after the CD-349 administration. The CBV was also increased. The mean arterial blood pressure was decreased by 39.8 ± 7.3 mmHg (p < 0.01) 1 min and 34.4 ± 5.5 mmHg (p < 0.01) 5 min after drug injection. Thereafter, the blood pressure gradually returned to the pre-drug level. From these results it is suggested that CD-349 exerts direct vasodilatory action via inhibition of calcium influx across vascular cell membranes into cerebral vessels.

UR - http://www.scopus.com/inward/record.url?scp=0023865444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023865444&partnerID=8YFLogxK

M3 - Article

C2 - 3370067

AN - SCOPUS:0023865444

VL - 38

SP - 221

EP - 224

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 2

ER -